Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

Authors
Sohn, Sang KyunOh, Suk JoongKim, Byung SooRyoo, Hun MoChung, Joo SeopJoo, Young DonBang, Soo MeeJung, Chul WonKim, Dong HwanYoon, Sung SooKim, In HoLee, Hong GhiWon, Jong HoMin, Yoo HongCheong, June WonPark, Joon SeongEom, Ki SeongHyun, Myung SooKim, Min KyoungKim, HawkPark, Moo RimPark, JinnyKim, Chul SooKim, Hyeoung JoonKim, Yeo KyeoungPark, Eun KyungZang, Dae YoungJo, Deog YeonMoon, Joon HoPark, Seon Yang
Issue Date
6월-2011
Publisher
INFORMA HEALTHCARE
Keywords
Chronic myeloid leukemia; imatinib; trough blood level; cytogenetic response; molecular response
Citation
LEUKEMIA & LYMPHOMA, v.52, no.6, pp.1024 - 1029
Indexed
SCIE
SCOPUS
Journal Title
LEUKEMIA & LYMPHOMA
Volume
52
Number
6
Start Page
1024
End Page
1029
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/112372
DOI
10.3109/10428194.2011.563885
ISSN
1042-8194
Abstract
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 +/- 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with < 1000: 80.6% vs. 19.4%; >= 1000: 94.6% vs. 5.4%; p=0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with < 1000: 3.2% vs. 96.8%; >= 1000: 21.4% vs. 78.6%; p=0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of >= 1000 compared with those with a level of < 1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (< 1000 ng/mL).
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE